Compare LBRX & IGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LBRX | IGR |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 602.6M | 645.2M |
| IPO Year | N/A | N/A |
| Metric | LBRX | IGR |
|---|---|---|
| Price | $25.69 | $4.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $50.67 | N/A |
| AVG Volume (30 Days) | 209.4K | ★ 702.6K |
| Earning Date | 05-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.93% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.40 | $4.15 |
| 52 Week High | $27.55 | $5.37 |
| Indicator | LBRX | IGR |
|---|---|---|
| Relative Strength Index (RSI) | 59.48 | 44.46 |
| Support Level | $22.39 | $4.20 |
| Resistance Level | $27.55 | $5.04 |
| Average True Range (ATR) | 1.49 | 0.10 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 63.31 | 50.91 |
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.
CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.